Euro-Med Laboratories Philippines (PHS:EURO) Debt-to-Equity : 0.69 (As of Dec. 2023)

View and export this data going back to 1998. Start your Free Trial

What is Euro-Med Laboratories Philippines Debt-to-Equity?

Euro-Med Laboratories Philippines's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₱3,283 Mil. Euro-Med Laboratories Philippines's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₱756 Mil. Euro-Med Laboratories Philippines's Total Stockholders Equity for the quarter that ended in Dec. 2023 was ₱5,845 Mil. Euro-Med Laboratories Philippines's debt to equity for the quarter that ended in Dec. 2023 was 0.69.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Euro-Med Laboratories Philippines's Debt-to-Equity or its related term are showing as below:

PHS:EURO' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.59 Med: 0.66 Max: 0.77
Current: 0.69

During the past 13 years, the highest Debt-to-Equity Ratio of Euro-Med Laboratories Philippines was 0.77. The lowest was 0.59. And the median was 0.66.

PHS:EURO's Debt-to-Equity is ranked worse than
77.75% of 854 companies
in the Drug Manufacturers industry
Industry Median: 0.29 vs PHS:EURO: 0.69

Euro-Med Laboratories Philippines Debt-to-Equity Historical Data

The historical data trend for Euro-Med Laboratories Philippines's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Euro-Med Laboratories Philippines Debt-to-Equity Chart

Euro-Med Laboratories Philippines Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.72

0.66

0.61

0.65

0.69

Euro-Med Laboratories Philippines Quarterly Data
	Dec17	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.65	0.62	0.62	0.62	0.69

Competitive Comparison of Euro-Med Laboratories Philippines's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Euro-Med Laboratories Philippines's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Euro-Med Laboratories Philippines's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Euro-Med Laboratories Philippines's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Euro-Med Laboratories Philippines's Debt-to-Equity falls into.

Euro-Med Laboratories Philippines Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Euro-Med Laboratories Philippines's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3282.567	+	756.39)	/	5845.188
	=	0.69

Euro-Med Laboratories Philippines's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3282.567	+	756.39)	/	5845.188
	=	0.69

Euro-Med Laboratories Philippines (PHS:EURO) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Euro-Med Laboratories Philippines Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Euro-Med Laboratories Philippines's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Euro-Med Laboratories Philippines (PHS:EURO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Euro-Med Laboratories Philippines Inc (PHS:EURO) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

San Marcelino Street, 1000 United Nations Avenue corner, PPL Building, 2nd floor, Manila, PHL, 1000

Website

http://www.euromedlab.net

Euro-Med Laboratories Philippines Inc is a pharmaceutical-based company that engages in the manufacture of pharmaceutical products such as large and small volume parenterals and other solutions. The company also manufactures sterile water for the injection, and other solutions such as ophthalmic, inhalation, irrigation and dialysis. It operates through the following segments: The Manufacturing pharmaceutical segment involves the manufacturing of pharmaceutical products. The Health and other care Service segment operates a dialysis center. Development and operation of quick-service restaurant segment include operations of the quick-service restaurant, catering, food production and other related services.

Euro-Med Laboratories Philippines (PHS:EURO) Headlines

No Headlines